Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Opto-chemical and laser properties of FLTX1, a novel fluorescent tamoxifen derivative, and its potential applications in breast cancer photodynamic chemotherapy

  • Díaz, Mario
  • Scholz, Laura E.
  • Marrero-Alonso, Jorge
  • Boto, Alicia
  • Marín, Raquel
  • Lobo, Fernando
  • Hernández, Dácil
  • Amesty, Ángel
  • Estévez-Braun, Ana
  • Quinto-Alemany, David
  • Puertas-Avedaño, Ricardo
  • Lahoz Zamarro, Fernando
Tamoxifen is the most common antiestrogen used in the chronic treatment of breast cancer. In these cells, it mainly binds to intracellular receptors (estrogen receptor alpha, ERα) and antagonizes the binding of its cognate ligand, 17β-estradiol, thereby preventing uncontrolled hormone-dependent cellular proliferation and growth. In the last decade, in our laboratories we have developed and characterized different tamoxifen derivatives, including a novel fluorescent tamoxifen conjugate: FLTX1. FLTX1 is formed by the covalent binding of tamoxifen to a common fluorescent biomarker NBD. This new prodrug was originally designed as a fluorescent biomarker to localize intracellular targets, which not only keeps the pharmacological activity of tamoxifen but also adds a luminescent functionality. Strikingly, the quantum efficiency of FLTX1 is so high that laser emission has been obtained as an emerging property. In this review, we will show its laser properties under three different configurations. First, as amplified spontaneous emission or mirrorless laser; second, through the evanescent field of WGMs of a ring resonator around an optical fiber; and finally as random laser in uterine tissues impregnated with the prodrug. Further, we observed another emergent property for FLTX1: this molecule, but not tamoxifen alone or NBD, was able to generate reactive oxygen species (ROS) upon irradiation. This property is extremely interesting as FLTX1 might be used for photodynamic therapy. Under this paradigm, FLTX1 would act as a sensitizer in ERα-overexpressing cells (which feature the most prevalent form of hormone-dependent breast cancer), causing cell death in ERα+ cells but reducing damage to other non-cancer (healthy) cells or surrounding tissues. We show here time resolved fluorescence results that suggest molecular aggregations, which could explain the subsequent generation of ROS. This is an original cancer therapy strategy that combines the pharmacological properties of a new tamoxifen derivative and its laser dye features with a highly selective photodynamic therapy., Supported by Research grant SAF2014-61644-EXP from MINECO (Spain) to M.D. Partially supported by Agencia Estatal de Investigación (AEI, grant ref. MAT2016-79866-R to F.L.), SAF2015-65113-C2-1-R and SAF2017-84454-R (from MINECO) to A.E. and R.M., respectively. DH and DQA were hired by Universidad de La Laguna. FL was recipient of contract from Torres Quevedo Programme (MINECO) and incorporated in BIOSIGMA SL (Spain)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Colocalization of estrogen receptors with the fluorescent tamoxifen derivative, FLTX1, analyzed by confocal microscopy

  • Morales, Araceli
  • Marín, Raquel
  • Marrero-Alonso, Jorge
  • Boto, Alicia
  • Díaz, Mario
Tamoxifen is a selective estrogen receptor modulator that competitively binds the ligand-binding domain of estrogen receptors. Binding of tamoxifen displaces its cognate ligand, 17β-estradiol, thereby hampering the activation of estrogen receptors. Cellular labeling of ER is typically carried out using specific antibodies which require permeabilization of cells, incubation with secondary antibodies, and are expensive and time consuming. In this article, we describe the usefulness of FLTX1, a novel fluorescent tamoxifen derivative, which allows the labeling of estrogen receptors in immunocytochemistry and immunohistochemistry studies, both under permeabilized and non-permeabilized conditions. Further, besides labeling canonical estrogen receptors, this novel fluorescent probe is also suitable for the identification of unconventional targets such membrane estrogen receptors as well as other noncanonical targets, some of which are likely responsible for the number of undesired side effects reported during long-term tamoxifen treatments., This work has been supported by grants SAF2010-22114-C02-01/02 (MD & RM), SAF2014-61644-EXP (MD)and SAF-2013-48399-R (AB) from Ministerio de Economía y Competitividad (Spain), Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Opto-Chemical and laser properties of a novel fluorescent antiestrogen derivative and its potential applications in breast cancer photodynamic chemotherapy

  • Díaz, Mario
  • Scholz, Laura E.
  • Boto, Alicia
  • Marín, Raquel
  • Puertas-Avedaño, Ricardo
  • Lobo, Fernando
  • Hernández, Dácil
  • Quinto-Alemany, David
  • Lahoz Zamarro, Fernando
Trabajo presentado en SHIFT 2017-Spectral Shaping for Biomedical and Energy Applications, celebrado en Tenerife (España) del 13 al 17 de noviembre de 2017., Tamoxifen is the most common antiestrogen used in the chronic treatment of breast cancer. In these cells, it mainly binds to intracellular receptors (estrogen receptor alpha, ER) and antagonizes the binding of its cognate ligand, 17ß-estradiol, thereby preventing uncontrolled hormonedependent cellular proliferation and growth. In the last decade, in our laboratories we have developed and characterized different tamoxifen derivatives, including a novel fluorescent tamoxifen conjugate: FLTX1. FLTX1 is formed by the covalent binding of tamoxifen to a common fluorescent biomarker NBD. This new prodrug was originally designed as a fluorescent biomarker to localize intracellular targets, which not only keeps the pharmacological activity of tamoxifen but also adds a luminescent functionality. Strikingly, the quantum efficiency of FLTX1 is so high that laser emission has been obtained as an emerging property. In this presentation, we will show its laser properties under three different configurations. First, as amplified spontaneous emission or mirrorless laser; second, through the evanescent field of WGMs of a ring resonator around an optical fiber; and finally as random laser in uterine tissues impregnated with the prodrug. In consideration of these properties, we have moved a step forward, under the hypothesis that in combination with a photosensitizer, such Rose Bengal (RB), FLTX1 might be used for photodynamic therapy. Under this paradigm, the new complex would act as a sensitizer in ER - overexpressing cells (which feature the most prevalent form of hormone-dependent breast cancer). Thus, when optically excited, FLTX1 would transfer its energy to RB, which, in turn, would relax producing reactive oxygen species (ROS) that eventually would induce cell death. The advantage of using FLTX1 to activate RB is the selectivity exhibited by FLTX1 to target cells overexpressing ER , i.e. estrogen-dependent breast cancer cells. This approach would reduce the damage of other non-cancer (healthy) cells or surrounding tissues. We show here the results that confirm efficient energy transfer (FRET) between FLTX1 and RB, and demonstrate the subsequent generation of ROS. Moreover, we have designed a new FLTX1-RB complex covalently bound through a short linker and explored its opto-chemical properties. This is an original cancer therapy strategy that combines the pharmacological properties of tamoxifen and its laser dye features with a highly selective photodynamic therapy., Supported by Research grant SAF2014-61644-EXP from MINECO (Spain)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Modificación selectiva de péptidos: bibliotecas de posibles agentes antimicrobianos>

  • Hernández, Dácil
  • Saavedra, Carlos Javier
  • Romero Estudillo, Iván Omar
  • Pérez de la Lastra, José Manuel
  • Boto, Alicia
Trabajo presentado en la XXI Semana Científica “Antonio González”, celebrada en San Cristóbal de La Laguna, Tenerife (España) del 24 al 27 de octubre de 2017., La obtención de análogos de péptidos bioactivos o catalíticos es un área de gran interés para compañías farmacéuticas y químicas. En el proceso de optimización de la actividad de un péptido se preparan análogos en cada uno de los cuales se introduce una modificación respecto al de partida, y se determinan qué cambios incrementan el efecto deseado. En los procesos convencionales estos análogos tienen que fabricarse de novo, añadiendo un aminoácido tras otro, pero a medida que aumenta el tamaño del péptido este enfoque supone un gasto importante de tiempo y materiales. De ahí el interés por desarrollar métodos que permitan modificar selectivamente un residuo concreto del péptido sin afectar a los otros. En esta comunicación se describe un método eficaz para transformar un péptido de partida en una colección de derivados modificando las posiciones que se desean sin que se vean afectadas las otras. Las posiciones “modificables” son ocupadas inicialmente por residuos de serina, treonina o hidroxiprolina que pueden ser convertidos en una gran variedad de otros aminoácidos (Figura 1). Aunque en el péptido haya dos o más unidades de estos aminoácidos es posible modificar una sin que se afecten las otras. Esta metodología ha sido utilizada para preparar bibliotecas de posibles AMPs a partir de pocos péptidos de partida, acelerando la generación de quimiotecas para cribado de alta eficacia. Los péptidos se han estudiado contra varios patógenos de humanos y plantas de importancia agrícola., Financiación del Proyecto SAF-2013-48399-R, Plan Estatal de I+D, Ministerio de Economía, Industria y Competitividad (MINECO), y el Fondo Social Europeo (FSE). DH e IR agradecen al CSIC sus contratos JAE; DH está contratada actualmente por la ULL (proyecto SAF2014-61644-EXP, Plan Estatal I+D, MINECO) e IR es profesor del CIQ-UAEM. CJS agradece al Gob.Canarias su contrato de investigación; actualmente trabaja para BIOSIGMA SL (programa Torres Quevedo del MINECO)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Derivados fluorescentes del tamoxifeno: de sondas médicas a fototerapia

  • Hernández, Dácil
  • Lobo, Fernando
  • Saavedra, Carlos Javier
  • Boto, Alicia
  • Lahoz Zamarro, Fernando
  • Díaz, Mario
Trabajo presentado en la XXI Semana Científica “Antonio González”, celebrada en San Cristóbal de La Laguna, Tenerife (España) del 24 al 27 de octubre de 2017., El Tamoxifeno 1 es un modulador selectivo de los receptores de estrógeno, empleado como tratamiento preventivo y terapia contra el cáncer de mama. Recientemente hemos sintetizado un derivado fluorescente del tamoxifeno, el FLTX1 2, que se ha usado como sonda para estudiar el mecanismo de acción del fármaco y sus efectos secundarios. El FLTX 2 ha permitido estudiar las interacciones con la diana farmacológica (receptor de estrógenos, ER) y además identificar nuevos receptores biológicos, explicando varios efectos secundarios de importancia.En estos estudios, se ha observado que el FLTX1 2 presenta una actividad como modulador selectivo de los receptores de estrógeno similar a la del tamoxifeno, a la vez que disminuyen los efectos secundarios debidos a efectos estrogénicos uterotróficos, lo que podría servir para diseñar derivados mejorados del fármaco. Por otra parte, se ha descubierto que esta molécula es capaz de actuar como pigmento láser (y emitir luz láser) al ser irradiada con luz visible, lo que resulta muy prometedor en fototerapia.La comunicación comenta también los nuevos compuestos (ej. producto 3 y derivados) desarrollados por el grupo para terapia fotodinámica., Este trabajo se financió con el proyecto SAF2014-61644-EXP de la convocatoria EXPLORA del Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica, Ministerio de Economía, Industria y Competitividad, así como con fondos FEDER y FSE (European Funds for Regional Development/European Social Funds). DH agradece a la Universidad de La Laguna su contrato postdoctoral (proyecto SAF2014-61644-EXP, Plan Estatal I+D, MINECO), y FL y CS agradecen al MINECO sus contratos Torres Quevedo para incorporación a empresas (BIOSIGMA SL)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Nuevos métodos de escisión-adición para obtener compuestos de alto valor añadido

  • Carro Sabina, Carmen
  • Boto, Alicia
  • Hernández, Dácil
  • García Llanos, Gabriel
Trabajo presentado en la XXI Semana Científica “Antonio González”, celebrada en San Cristóbal de La Laguna, Tenerife (España) del 24 al 27 de octubre de 2017., La obtención de productos de alto valor añadido a partir de sustratos abundantes y de bajo coste es un área de gran interés industrial.Para preparar estos productos hemos desarrollado procesos químicos dominó o secuenciales que encadenan varias reacciones, sin necesidad de purificar los productos intermedios.Con ello se ahorran tiempo y materiales con respecto a los procesos tradicionales, y se genera menor impacto medioambiental. Además, los procesos comentados no emplean promotores metálicos, la toxicidad de los reactivos es baja y la purificación de los productos es sencilla. En esta comunicación se comenta la aplicación de procesos de escisión-adición a derivados de hidroxiprolina, y la modificación de los productos resultantes para obtener una importante variedad de aminas y de análogos de amino ácidos., Este trabajo se financió con el Proyecto SAF-2013-48399-R, Plan Estatal de I+D, Ministerio de Economía y Competitividad (MINECO), y el Fondo Social Europeo (FSE). DH agradece al CSIC su contrato JAE; actualmente está contratada por la ULL (proyecto SAF2014-61644-EXP, Plan Estatal I+D, MINECO), mientras que CC trabaja para BIOSIGMA SL (programa Doctorados Industriales del MINECO)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Enhanced green fluorescent protein in optofluidic Fabry-Perot microcavity to detect laser induced temperature changes in a bacterial culture

  • Lahoz, F.
  • Martín, I. R.
  • Walo, D.
  • Freire, R.
  • Gil-Rostra, J.
  • Yubero, Francisco
  • González-Elipe, Agustín R.
Thermal therapy using laser sources can be used in combination with other cancer therapies to eliminate tumors. However, high precision temperature control is required to avoid damage in healthy surrounding tissues. Therefore, in order to detect laser induced temperature changes, we have used the fluorescence signal of the enhanced Green Fluorescent Protein (eGFP) over-expressed in an E. coli bacterial culture. For that purpose, the bacteria expressing eGFP are injected in a Fabry-Perot (FP) optofluidic planar microcavity. In order to locally heat the bacterial culture, external infrared or ultraviolet lasers were used. Shifts in the wavelengths of the resonant FP modes are used to determine the temperature increase as a function of the heating laser pump power. Laser induced local temperature increments up to 6-7 °C were measured. These results show a relatively easy way to measure laser induced local temperature changes using a FP microcavity and using eGFP as a molecular probe instead of external nanoparticles, which could damage/alter the cell. Therefore, we believe that this approach can be of interest for the study of thermal effects in laser induced thermal therapies., This research was supported by Spanish Ministry of Economy and Competitiveness (Agencia Estatal de Investigación, AEI) and EU-FEDER (SAF2016-80626-R), (SAF2014-61644-EXP), (MAT2016-79866-R), (MAT2016-75586-C4-4-P).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A compact and portable optofluidic device for detection of liquid properties and label-free sensing

  • Lahoz, F.
  • Martín, I. R.
  • Walo, D.
  • Gil-Rostra, J.
  • Yubero, Francisco
  • González-Elipe, Agustín R.
Optofluidic lasers have been widely investigated over the last few years mainly because they can be easily integrated in sensor devices. However, high power pulse lasers are required as excitation sources, which, in practice, limit the portability of the system. Trying to overcome some of these limitations, in this paper we propose the combined use of a small CW laser with a Fabry-Perot optofluidic planar microcavity showing high sensitivity and versatility for detection of liquid properties and label-free sensing. Firstly, a fluorescein solution in ethanol is used to demonstrate the high performances of the FP microcavity as a temperature sensor both in the laser (high pump power above laser threshold) and in the fluorescence (low pump power) regimes. A shift in the wavelength of the resonan cavity modes is used to detect changes in the temperature and our results show that high sensitivities could be already obtained using cheap and portable CW diode lasers. In the second part of the paper, the demonstration of this portable device for label-free sensing is illustrated under low CW pumping. The wavelength positions of the optofluidic resonant modes are used to detect glucose concentrations in water solutions using a protein labelled with a fluorescent dye as the active medium., This research was supported by European Regional Development Funds program (EU-FEDER), Agencia Estatal de Investigación (AEI) and MINECO (SAF2014-61644-EXP), (MAT2013-40852-R), (MAT2013-46649-C4-4-P), (MAT2015-71070-REDC), (MAT2016-79866-R), (MAT2016-75586-C4-4-P), FUNCOAT (CSD2008-00023), and by the Junta de Andalucía (projects P12-FQM-2265 and P10-FQM-6900).